- Home
- IRON vs AAPG Comparison
IRON vs AAPG Comparison
Compare IRON & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- AAPG
- Stock Information
- Founded
- IRON 2017
- AAPG 2009
- Country
- IRON United States
- AAPG China
- Employees
- IRON N/A
- AAPG N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- AAPG Biotechnology: Pharmaceutical Preparations
- Sector
- IRON Health Care
- AAPG Health Care
- Exchange
- IRON Nasdaq
- AAPG Nasdaq
- Market Cap
- IRON 3.4B
- AAPG 3.6B
- IPO Year
- IRON N/A
- AAPG 2025
- Fundamental
- Price
- IRON $89.84
- AAPG $34.30
- Analyst Decision
- IRON Strong Buy
- AAPG Strong Buy
- Analyst Count
- IRON 12
- AAPG 3
- Target Price
- IRON $108.83
- AAPG $49.00
- AVG Volume (30 Days)
- IRON 531.4K
- AAPG 8.1K
- Earning Date
- IRON 11-06-2025
- AAPG 11-19-2025
- Dividend Yield
- IRON N/A
- AAPG N/A
- EPS Growth
- IRON N/A
- AAPG N/A
- EPS
- IRON N/A
- AAPG N/A
- Revenue
- IRON N/A
- AAPG $54,524,554.00
- Revenue This Year
- IRON N/A
- AAPG N/A
- Revenue Next Year
- IRON N/A
- AAPG $368.64
- P/E Ratio
- IRON N/A
- AAPG N/A
- Revenue Growth
- IRON N/A
- AAPG N/A
- 52 Week Low
- IRON $30.82
- AAPG $16.50
- 52 Week High
- IRON $95.95
- AAPG $48.45
- Technical
- Relative Strength Index (RSI)
- IRON 64.84
- AAPG 47.99
- Support Level
- IRON $83.00
- AAPG $30.93
- Resistance Level
- IRON $90.39
- AAPG $34.31
- Average True Range (ATR)
- IRON 3.70
- AAPG 0.81
- MACD
- IRON -0.40
- AAPG 0.26
- Stochastic Oscillator
- IRON 74.77
- AAPG 85.99
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
About AAPG Ascentage Pharma Group International American Depository Shares
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.